Indefinite Delivery Contract SPE2DU25D5323

The federal Indefinite Delivery Contract (IDC) SPE2DU25D5323, awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The $9,999,999,999 single-award IDC, with a period of performance through December 2036, serves as a prime vendor contract vehicle for delivering brand-name and generic drugs, specialty medications, vaccines, syringes, vials, and test kits across multiple therapeutic areas. This IDC aligns with DLA's planned Pharmaceutical Prime Vendor Global Program Generation V solicitation, which seeks to establish prime vendor contracts to provide worldwide pharmaceutical support to DoD customers, the U.S. Coast Guard, and other designated providers. The unrestricted, competitively awarded IDC enables efficient government procurement of essential medical commodities to address the healthcare needs of military personnel, veterans, and other federal beneficiaries through a streamlined contracting mechanism.

The original pre-solicitation describes DLA's intent to make multiple regional awards for the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items, with the aim of having at least three different contractors to enhance supply chain resiliency. The solicitation will be issued on a Lowest Price Technically Acceptable (LPTA) basis, with the selected vendors providing separate distribution fees for brand/generic and specialty pharmaceuticals to support normal operations and contingency requirements. This acquisition covers medical products in the 6505 stock catalog/schedule and the National Drug Code database, positioning AmerisourceBergen as a critical supplier of essential pharmaceutical and medical commodities to the U.S. military and federal healthcare programs.